#TilrayArmy🍀💰 – Tilray’s business hasn't collapsed to the same extent as its stock price; for those looking to invest in TLRY at the current price—around $4.23—it is worth noting that
$TLRY💰🍀 is starting to look like an attractive accumulation zone again. – Why it’s interesting now:
1. Valuation has become deeply depressed
$TLRY🍀💰 is down approximately 53% YTD and 65% over the past year as of the latest data.
* At the same time, the company reported FY2026 revenue of $915.5M (up 11%) and adjusted EBITDA of $61.1M, compared to the previous $55M.
* Cannabis revenue grew by 8%, and distribution revenue by 21%. 2. The balance sheet is stronger than it appears at first glance
Tilray reported approximately $235M in cash, restricted cash, and marketable securities, with net debt of only ~$0.7M at the end of FY2026.
This is significant because financing and debt have historically been among TLRY’s main issues. 3. The cannabis catalyst remains in play
The federal process regarding Schedule III status is still active. The DEA has officially confirmed that the rescheduling procedure is proceeding through the formal rulemaking process.